放射性 131I 在甲亢伴甲状腺结节中的应用价值

doi:10.3969/j.issn.1000-8535.2020.01.011

广州医药 ›› 2020, Vol. 51 ›› Issue (1): 46-49.DOI: 10.3969/j.issn.1000-8535.2020.01.011

放射性 ¹³¹I 在甲亢伴甲状腺结节中的应用价值

杜赐浩, 王鹏翔, 罗晓斌

广州华侨医院胃腸二外科(广州 525000)

收稿日期:2019-07-29 出版日期:2020-01-20 发布日期:2021-11-28

Application value of radioactivity ¹³¹I in hyperthyroidism with thyroid nodules

DU Cihao, WANG Pengxiang, LUO Xiaobin

Department of Gastrointestinal Surgery, Guangzhou Overseas Chinese Hospital, Guangzhou 525000, China

Received:2019-07-29 Online:2020-01-20 Published:2021-11-28

摘要/Abstract

摘要： 目的研究放射性 ¹³¹I 在甲亢伴甲状腺结节中的应用价值。方法纳入我院90例甲亢患者,根据其是否伴甲状腺结节分为无结节组(51例)、结节组(39例),均接受放射性 ¹³¹I 治疗。比较两组治疗总有效率,分析两组治疗前后血清甲状腺过氧化物酶抗体(TPOAb)、甲状腺球蛋白抗体(TGAb)、促甲状腺激素(TSH)、游离三碘甲腺原氨酸(FT3)及游离甲状腺素(FT4)水平。结果无结节组治疗总有效率74.51%,结节组为58.97%,差异无统计学意义(P＞0.05);两组治疗后TSH均高于治疗前(P＜0.05),FT3、FT4均低于治疗前(P＜0.05),TPOAb、TGAb较治疗前比较差异均无统计学意义(P＞0.05);无结节组治疗后FT3、FT4低于结节组(P<0.05),TPOAb、TGAb、TSH较结节组比较差异均无统计学意义(P＞0.05)。结论放射性 ¹³¹I 治疗甲亢伴甲状腺结节效果好,且操作简单,副作用少,值得临床推广使用。

关键词: 放射性 ¹³¹I, 甲亢, 甲状腺结节

Abstract: Objective To study the value of radioactivity ¹³¹I in hyperthyroidism with thyroid nodules. Methods Ninety patients with hyperthyroidism in our hospital were divided into non-nodule group (51 cases) and nodule group (39 cases) according to whether they had thyroid nodules or not. All patients received ¹³¹I radiation therapy. The total effective rate was compared between the two groups. The serum levels of thyroid peroxidase antibody (TPOAb), thyroglobulin antibody (TGAb), thyroid stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) were analyzed before and after treatment. Results The total effective rate was 74.51% in non-nodule group and 58.97% in nodule group, with no significant difference (P>0.05);after treatment, TSH was higher in both groups than that before treatment (P<0.05), FT3 and FT4 were lower than that before treatment (P<0.05), TPOAb and TGAb had no significant difference compared with that before treatment (P>0.05);FT3 and FT4 in nodule-free group were lower than those in nodule group (P<0.05). TPOAb, TGAb and TSH had no significant difference compared with nodule group (P>0.05). Conclusion Radioactive ¹³¹I treatment of hyperthyroidism with thyroid nodules has good effect, simple operation and few side effects, which is worthy of clinical application.

Key words: Radioactive ¹³¹I, Hyperthyroidism, Thyroid nodules

杜赐浩, 王鹏翔, 罗晓斌. 放射性 ¹³¹I 在甲亢伴甲状腺结节中的应用价值[J]. 广州医药, 2020, 51(1): 46-49.

DU Cihao, WANG Pengxiang, LUO Xiaobin. Application value of radioactivity ¹³¹I in hyperthyroidism with thyroid nodules[J]. Guangzhou Medical Journal, 2020, 51(1): 46-49.

参考文献

[1] 周雨, 张智伟. 甲状腺功能亢进症病因病机探析[J]. 河南中医, 2017, 37(10):1771-1773.
[2] 范景丽, 马玉琴, 汪春雷,等. 121例亚急性甲状腺炎患者流行病学及临床特点的回顾性分析[J]. 中华地方病学杂志, 2017, 36(5):338-341.
[3] 黄玉芹, 唐刚田, 郭见光. 甲状腺结节伴有甲亢的治疗体会[J]. 中国医药指南, 2016, 14(15):123-124.
[4] 吴茜, 王荣福. 放射性核素 ¹³¹I 在甲亢治疗中的应用现状和进展[J]. 标记免疫分析与临床, 2015, 22(1):66.
[5] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南——甲状腺功能亢进症[J]. 中华内科杂志, 2007, 46(10):876-882.
[6] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南——甲状腺结节[J]. 中华内科杂志, 2008, 47(10):867-868.
[7] 中华医学会核医学分会. ¹³¹I 治疗格雷夫斯甲亢指南(2013版)[J]. 中华内分泌代谢杂志, 2013, 29(6):448-459.
[8] 蒋宁一, 匡安仁, 谭建,等. ¹³¹I 治疗Graves甲亢专家共识(2010年)[J]. 中华核医学与分子影像杂志, 2010, 30(5):346-351.
[10] 周琦, 李诗骜, 姜珏, 等. 超声造影鉴别甲状腺钙化结节性质及其与年龄、性别的相关性分析[J]. 中华超声影像学杂志, 2016, 25(4):313-317.
[11] 彭可. ¹³¹I 治疗甲状腺功能亢进症临床效果影响因素探讨[J]. 医学信息, 2015, 7(14):329-329.
[12] 邓云. 影响131碘治疗甲亢的因素分析[J]. 中国保健营养旬刊, 2014, 24(4):1950-1951.
[13] 姚晓波, 张然, 金晓毛,等. 超声检查甲状腺功能亢进症伴有甲状腺结节者的临床特点和131碘治疗效果分析[J]. 中国临床保健杂志, 2017, 20(4):404-407.
[14] 张王峰, 马友凤, 周梅,等. 甲亢131碘治疗后早发甲减患者临床转归的分析[J]. 广西医科大学学报, 2016, 33(2):320-322.
[15] 吴邦国, 杨静升, 高小宏. ¹³¹I 治疗Graves病早发甲减发生的预防与处理[J]. 中国社区医师, 2018, 34(14):60-62.

放射性 ¹³¹I 在甲亢伴甲状腺结节中的应用价值

Application value of radioactivity ¹³¹I in hyperthyroidism with thyroid nodules

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价